COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR

ABSTRACT

The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.

[FIGURE 3]